Protara Therapeutics Inc. [NASDAQ: TARA] gained 7.72% on the last trading session, reaching $18.28 price per share at the time.
Protara Therapeutics Inc. represents 5.84 million in outstanding shares, while the company has a total market value of $177.13 million with the latest information. TARA stock price has been found in the range of $16.70 to $18.99.
If compared to the average trading volume of 33.56K shares, TARA reached a trading volume of 1058911 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Protara Therapeutics Inc. [TARA]:
Guggenheim have made an estimate for Protara Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 29, 2020.
The Average True Range (ATR) for Protara Therapeutics Inc. is set at 1.35 The Price to Book ratio for the last quarter was 1.80.
Trading performance analysis for TARA stock
Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91. With this latest performance, TARA shares dropped by -7.58% in over the last four-week period, additionally sinking by -20.66% over the last 6 months – not to mention a rise of 79.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TARA stock in for the last two-week period is set at 43.32, with the RSI for the last a single of trading hit 54.32, and the three-weeks RSI is set at 41.25 for Protara Therapeutics Inc. [TARA]. The present Moving Average for the last 50 days of trading for this stock 21.62, while it was recorded at 17.15 for the last single week of trading, and 26.98 for the last 200 days.
Protara Therapeutics Inc. [TARA]: A deeper dive into fundamental analysis
Protara Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.50 and a Current Ratio set at 9.50.
Protara Therapeutics Inc. [TARA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Protara Therapeutics Inc. posted -3.2/share EPS, while the average EPS was predicted by analysts to be reported at -3.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TARA.
An analysis of insider ownership at Protara Therapeutics Inc. [TARA]
There are presently around $72 million, or 38.10% of TARA stock, in the hands of institutional investors. The top three institutional holders of TARA stocks are: OPALEYE MANAGEMENT INC. with ownership of 2,208,472, which is approximately 0% of the company’s market cap and around 5.60% of the total institutional ownership; IKARIAN CAPITAL, LLC, holding 527,964 shares of the stock with an approximate value of $9.65 million in TARA stocks shares; and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), currently with $7.91 million in TARA stock with ownership of nearly 0% of the company’s market capitalization.
25 institutional holders increased their position in Protara Therapeutics Inc. [NASDAQ:TARA] by around 292,841 shares. Additionally, 11 investors decreased positions by around 286,321 shares, while 4 investors held positions by with 3,380,806 shares. The mentioned changes placed institutional holdings at 3,959,968 shares, according to the latest SEC report filing. TARA stock had 12 new institutional investments in for a total of 69,044 shares, while 7 institutional investors sold positions of 186,735 shares during the same period.